Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
6,876actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: KarXT (xanomeline and trospium)
Primary outcomes
what the primary-completion date above is the date OFNumber of all-cause and schizophrenia-related healthcare encounters per participant
measured Baseline and up to 6 months
Number of participants adherent to KarXT (proportion of days covered ≥80%)
measured Baseline and up to 6 months
Time to discontinuation of KarXT
measured Baseline and up to 6 months
KarXT initial dose (index dose)
measured Baseline
Number of of participants with dose increases or decreases
measured Baseline and up to 6 months
Number of participants using concomitant antipsychotic and anticholinergic medications
measured Baseline and up to 6 months
Number of participants with comorbidities
measured Baseline and up to 6 months
Number of participants with gastrointestinal adverse events
measured Baseline and up to 6 months
Number of participants with documented schizophrenia symptoms
measured Baseline and up to 6 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed